Thomas Jefferson University

Jefferson Digital Commons
Department of Neurology Faculty Papers

Department of Neurology

6-28-2019

Astragaloside IV protects neurons from microglia-mediated cell
damage through promoting microglia polarization.
Jingwen Yu
Shanxi Datong University

Minfang Guo
Shanxi Datong University

Yanhua Li
Shanxi Datong University

Huiyu Zhang
Shanxi Datong University

Zhi
Chai
Follow
this and additional works at: https://jdc.jefferson.edu/neurologyfp
Shanxi University of Chinese Medicine
Part of the Neurology Commons

Let us know how access to this document benefits you
See next page for additional authors

Recommended Citation
Yu, Jingwen; Guo, Minfang; Li, Yanhua; Zhang, Huiyu; Chai, Zhi; Wang, Qing; Yan, Yuqing; Yu,
Jiezhong; Liu, Chunyun; Zhang, Guang-Xian; and Cungen, Ma, "Astragaloside IV protects neurons
from microglia-mediated cell damage through promoting microglia polarization." (2019).
Department of Neurology Faculty Papers. Paper 200.
https://jdc.jefferson.edu/neurologyfp/200
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Neurology Faculty Papers by an authorized administrator of the Jefferson
Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors
Jingwen Yu, Minfang Guo, Yanhua Li, Huiyu Zhang, Zhi Chai, Qing Wang, Yuqing Yan, Jiezhong Yu,
Chunyun Liu, Guang-Xian Zhang, and Ma Cungen

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/neurologyfp/200

Original paper

Astragaloside IV protects neurons from microglia-mediated
cell damage through promoting microglia polarization

Jingwen Yu1*, Minfang Guo1*, Yanhua Li1, Huiyu Zhang1, Zhi Chai2, Qing Wang2, Yuqing Yan1, Jiezhong Yu1,
Chunyun Liu1, Guangxian Zhang1,3, Ma Cungen1
1Institute of Brain Science, Shanxi Key Laboratory of Inflammatory Neurodegenerative Diseases, Shanxi Datong University, Datong
037009, China, 2Shanxi University of Chinese Medicine, Jinzhong, China, 3Department of Neurology, Thomas Jefferson University,
Philadelphia, PA, USA

*Jingwen

Yu and Minfang Guo contributed equally to this work.

Folia Neuropathol 2019; 57 (2): 170-181		

DOI: https://doi.org/10.5114/fn.2019.86299

Abstract
Astragaloside IV (AST-IV) is a major active ingredient of astragalus, with a neuroprotective effect. The current study is
aimed to investigate the impact of AST-IV on the M1/M2 microglial activation in response to lipopolysaccharide (LPS)
stimulation, how AST-IV attenuated microglia-mediated neuronal damage, and the molecular mechanisms underlying
AST-IV’s protection of neurons against microglia-mediated neuronal damage. Our results showed that AST-IV partially
protected microglia from death evoked by LPS and downregulated the release of pro-inflammatory (M1) mediators
including interleukin (IL)-1β, IL-6, tumour necrosis factor α (TNF-α) and nitric oxide, as well as the expression of Toll-like
receptors 4 (TLR4), MyD88, and nuclear factor κB (NF-κB) of these cells. In contrast, AST-IV elevated the production of
anti-inflammatory cytokine IL-10 and expression of arginase 1, an M2 marker of microglia, whose conditioned medium
promoted PC12 neurons survival. These results indicate that AST-IV exerts an anti-inflammatory effect on microglia,
possibly through inhibiting TLR4/NF-κB signalling pathways, and protects neurons from microglia-mediated cell death
through conversion of microglia from inflammatory M1 to an anti-inflammatory M2 phenotype.
Key words: astragaloside IV, neuroinflammatory, neurons, microglia polarization, TLR4 intracellular pathways.

Introduction
Microglia, the innate immune cells in the central nervous system (CNS), can remove the damaged nerves, patches, infectious substances, secrete
immune regulatory factors, and protect neurons.
Excessive activation of microglia, however, is the
cause of neurodegenerative diseases such as Alzheimer’s disease (AD), multiple sclerosis (MS), Parkinson’s disease (PD) and amyotrophic lateral sclerosis
(ALS) [5,14,27]. Activated microglia release a lot of
nerve toxicity factors such as nitric oxide (NO) and

superoxide free radicals (ROS) and inflammatory
factors, and lead to neurodegenerative disease [29].
Thus, it has a great significance for the regulation of
activated microglia to treat various neurodegenerative diseases.
Neuroinflammation contributes to a wide variety of neurodegenerative diseases, and is strongly
linked with neuronal loss or dysfunction in these
diseases. The activation of microglia plays a key
role in neuroinflammation and activated microglia kill neurons through a number of mechanisms,
such as acute activation of the phagocyte NADPH
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oxidase (PHOX), expression of the inducible nitric
oxide synthase (iNOS) and release of inflammatory
factors [4]. Like peripheral macrophages, microglia
activation has been characterized by a recognized
number of phenotypes: namely, the surveillant/nonpolarized phenotype (M0), the classic activation type
(M1) and the selective activation type (M2) [7]. The
M1 phenotype or classical activated microglia can
be induced by lipopolysaccharide (LPS), interferon γ
(IFN-γ), tumour necrosis factor α (TNF-α), hypoxia,
and β-amyloid with increased production of proinflammatory cytokines, chemokines and oxidative
metabolites such as TNF-α, interleukin 1β (IL-1β),
IL-6, iNOS, NO, matrix metalloproteinases (MMPs)
reactive oxygen and nitro active species, thereby exacerbating inflammation and contributing
to neuron damage and death. In contrast, M2-like
microglia can suppress inflammation and promote
neural repair and regeneration by secreting anti-inflammatory cytokines, such as transforming growth
factor β (TGF-β), IL-4, IL-10, and neurotrophic factors
such as glial cell-derived neurotrophic factor (GDNF),
brain-derived neurotrophic factor (BDNF) and platelet-derived growth factor (PDGF) [18]. Induction of
M2-like microglia is, therefore, an attractive strategy
for the treatment of neurological diseases with neuroinflammation based on their protective functions.
Astragaloside IV (AST-IV) is a small molecular
saponin and a major active ingredient of Astragalus membranaceus, a widely used traditional herbal
medicine. It was reported that AST-IV exerted antiinflammatory, antivirus, anti-aging, immunomodulatory, and organ protective effects [26,38]. AST-IV can
reduce the damage and apoptosis of hippocampal
neurons in rats and promote the survival of primary
cells in the cerebral cortex and the growth of axons
[10,13]. In vivo experiments also proved that AST-IV
can reduce CNS damage, alleviate the incidence of
EAE mice, reduce the loss of dopamine neurons, and
have a neuroprotective effect [12].
To better understand the anti-inflammatory
capacity of AST-IV in the CNS, microglia were stimulated by LPS, the effect of AST-IV was examined and
the molecular mechanism was discussed. This study
will provide a potential for AST-IV application in
neurodegenerative diseases.
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Material and methods
BV-2 cell culture and treatment
The BV-2 immortalized microglial cell line was
purchased from the National Infrastructure of Cell
Line Resource, Beijing, China, and cultured in Dulbecco’s modified Eagle medium (DMEM; Gibco,
Grand Island, NY, USA), supplemented with 10% foetal bovine serum (FBS; HyClone, Logan, Utah, USA),
100 U/ml penicillin, and 100 μg/ml streptomycin
(Gibco) at 37°C in a humidified cell incubator with
a 95%/5% (v/v) mixture of air and CO2.
AST-IV is major active component of astragaloside
that is obtained from traditional Chinese medicine
Astragali radix (Sigma, St. Louis, MO, USA). After BV-2
cells had been cultivated overnight, LPS (Sigma) was
added at a final concentration of 1 μg/ml and ASTIV was added at final concentrations of 1 μM/l and
5 μM/l. Wells added only with PBS served as controls. Cells in all groups were then cultured for 24 h.

PC12 cell culture
Pheochromocytoma (PC12) neurons were cultured in DMEM, supplemented with 10% FBS, 100 U/ml
penicillin, and 100 μg/ml streptomycin at 37°C in
a humidified cell incubator with a 95%/5% (v/v)
mixture of air and CO2. Cells were subcultured
3 times a week at a density of 5 × 105/ml and incubated with BV-2-conditioned medium for 24 h.

Cell viability
Cell viability of BV-2 microglia was measured by
MTT assay. Briefly, BV-2 cells (4 × 104/ml) were inoculated on 96-well plates, and cultured with AST-IV
(0, 0.5, 1, 2, 5, 10, 20, 50, 100 μmol/l) for 24 h, or
cultured with BV-2-conditioned medium for 24 h.
Then 100 μl of 0.5 mg/ml MTT solution was added
to each well, and the plates were incubated at 37°C
for an additional 4 h. Plates were then centrifuged
to remove the supernatants, and the crystals were
dissolved in 150 μl of DMSO. Cell viability was measured by the optical density (OD) at 490 nm using
a quantified microplate reader (Biotek Labsystem,
Vermont, USA). All results were confirmed by replication in at least 3 independent experiments. Cell
viability (%) = (OD value of the experimental well
– OD value of the zero-setting well) / (OD value of
the control well – OD value of the zero-setting well)
× 100%.
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Nitrite assay
Nitric oxide was assayed by the Griess reaction to
measure the end product nitrite. Supernatants of cultured cells (100 μl) were mixed with 100 μl of Griess
reagent for 10 min at RT. Absorbance was measured
at 510 nm in a quantified microplate reader. Concentrations of nitrite were determined by a standard
curve of sodium nitrite (Beyotime, Shanghai, China). Determinations were performed and repeated in
3 independent experiments.

Cytokine ELISA assay
Collected supernatants were measured for the concentrations of IL-1β, IL-6, TNF-α, IL-4, and IL-10 by sandwich ELISA kits (PeproTech, Rocky Hill, NJ, USA) following
the manufacturer’s instructions. All results were repeated in 3 independent experiments. Concentrations of
cytokines were quantified by referencing to a standard
curve and expressed as pg/ml.

Western blot analysis

Immunofluorescent staining

Homogenized cells were dissolved in RIPA Lysis Buffer (Beyotime) supplemented with protease inhibitors.
Protein concentration was measured by BCA (Beyotime).
150

Cell viability (% of control)

Cell extracts (30 μg) were loaded onto 10% SDS-polyacrylamide gels, transferred onto a nitrocellulose membrane (Merck Millipore, Tullagreen Carrigtwohill, Cork,
Ireland), blocked by 5% milk at room temperature (RT) for
2 h. Membranes were incubated at 4°C overnight with
primary antibodies Toll-like receptors 4 – TLR4 (1 : 1000,
2246, Cell Signaling, Boston, USA), nuclear factor κB –
NF-κB (p65) (1 : 1000, 30335, Cell Signaling), myeloid
differentiation factor – MyD88 (1 : 1000, ab2064, Abcam,
Cambridge, UK), IL-1β (1 : 1000, Abcam, ab200478), iNOS
(1 : 1000, ADI-905-431-1, Enzo Life Sciences, NY, USA),
Arg-1 (1 : 1000, 610708, BD Biosciences, NY, USA), and
β-actin (1 : 10,000, 4970, Cell Signaling). Horseradish peroxidase-conjugated secondary antibody goat anti-mouse
(1 : 10,000, E030110-01, Earth, San Francisco, CA, USA) and
goat anti-rabbit (1 : 10,000, E030120-01, Earth) were incubated for 2 h on the next day. Immunoblots were measured
by Quantity Software (Bio-Rad, Hercules, CA, USA). To compare the protein loading, β-actin was used as the optical
density of internal reference.
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BV-2 microglia were cultured and treated based on
experimental requirements in a 24-well plate with slides.
BV-2 microglia were fixed with 4% paraformaldehyde
for 30 min and stained with the following antibodies:
TLR4 (1 : 1000), NF-κB (1 : 1000), iNOS (1 : 1000), Arg-1
(1 : 1000), and kept overnight at 4°C. The next day, Alexa
Fluor 488-conjugated secondary antibodies (1 : 1000;
Invitrogen, Eugene, USA) or Alexa Fluor 555-conjugated
secondary antibodies (1 : 1000; Invitrogen) were added
at RT for 2 h. The stained slides were examined by fluorescence microscope (Olympus, Tokyo, Japan).
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Results
Effect of AST-IV on microglia viability
0

0
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Fig. 1. The cell viability did not exhibit any statistical difference after exposure to less than or equal
to 5 μmol/l and was markedly decreased after
exposure to 10 μmol/l of AST-IV. The BV-2 cells
were cultured in 96-well plates in the absence or
presence of AST-IV (0, 0.5, 1, 2, 5, 10, 20, 50, 100
µmol/l) for 24 h. Cell viability was measured by
the MTT assay. The quantitative analysis was performed based on 3 independent experiments with
similar results. **p < 0.01, ***p < 0.00 vs. 0 µmol/l.

172

The viability of BV-2 microglia at different AST-IV
concentrations was tested by MTT. The effect of AST-IV
on the viability of BV-2 microglia viability of less than or
equal to 5 μmol/l did not exhibit any statistical difference (p > 0.05) compared with the control group (Fig. 1).
Cell viability was markedly decreased after exposure to
10 μmol/l of AST-IV, indicating that a higher dose of ASTIV is cytotoxic. The dose of AST-IV is different from that
in other articles, on account of DMSO as the auxiliary
solvent, which may have an effect on cell toxicity. Concentrations of AST-IV at 1 and 5 μmol/l were, therefore,
used in the following experiments.
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Fig. 2. AST-IV inhibited the activation of BV-2 cells that were treated with LPS and showed a resting morphology. AST-IV effectively inhibited the production of NO. The BV-2 cells were cultured in 24-well plates
in the absence or presence of LPS (1 μg/ml)/AST-IV (1 μmol/l and 5 μmol/l) for 24 h. The cell morphology
was obtained by bright field imaging using an inverted Olympus microscope. Representative pictures were
exhibited on BV-2 cells (A), and release of NO was detected by Griess assay (B). The quantitative analysis
was performed based on 3 independent experiments with similar results. ∆∆p < 0.01 vs. LPS(–) AST-IV(–),
**p < 0.01 vs. LPS(+) AST-IV(–).

Effect of AST-IV on microglia
morphology and nitric oxide
production
Resting BV-2 microglia is characterized by
rounded and fusiformis cell bodies, clear in cell
edge and bright cytoplasm, whereas activated
BV-2 cellular morphology like a broken egg or
a worm, swollen cell body, blur in the edge, and
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dim cytoplasm. Cell morphology changed after
24 h of treatment with PBS, LPS (1 μg/ml) and
AST-IV (1 and 5 μmol/l). A resting morphology
was observed in PBS-treated microglia, and cells
treated with LPS exhibited an activated one
(Fig. 2A). In contrast, microglia activation was
inhibited by AST-IV, which showed a resting morphology.
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Fig. 3. AST-IV significantly inhibited the expression of Myd88, TLR4 and NF-κB in BV-2 cells. The BV-2 cells
were cultured in 24-well/6-well plates in the absence or presence of LPS (1 μg/ml)/AST-IV (1 μmol/l and
5 μmol/l) for 24 h. Protein levels of TLR4 and NF-κB were measured by immunocytochemistry staining
(A and B) and Western blot assay (C). Quantitative results are from three independent experiments with
similar results. ∆p < 0.05, ∆∆p < 0.01 vs. LPS(–) AST-IV(–), *p < 0.05 vs. LPS(+) AST-IV(–).

The production of nitrite, a major end product
of NO metabolism, was detected in the supernatants of BV-2 cells by Griess reagent. The results
showed that LPS strongly stimulated the production of nitrite (Fig. 2B; p < 0.01), and this production was effectively inhibited by AST-IV treatment (Fig. 2B; p < 0.05).
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Effect of AST-IV on LPS-induced TLR4/
MyD88/NF-κB signalling in BV-2 cells
Toll-like receptors (TLRs) are a key component of the
innate immune system that defences against pathogens
and the development of adaptive immunity, releases
cytokines, increases costimulatory molecule expression,
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Fig. 3. Cont.

and provides the necessary activated signal to form
the acquired immune reaction. Myeloid differentiation factor (MyD88) is a key joint molecule in the TLRs
signal path. MyD88 contains two domains, one is carboxyl terminal homologous binding to TLRs, the other
is amino acid terminal binding to the death domain of
IL-1 receptor associate kinase (IRAK), which causes IRAK
phosphorylation. A series of activated reaction causes
the activation of Iκbα, eventually leads to activate NF-κB
and transposition, releases of inflammatory cytokines,
which induces inflammatory response process.
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We then determined the expression of TLR4,
MyD88 and NF-κB, all important M1-like molecules, by immunostaining. Our results showed
that the expression of these molecules was upregulated by LPS stimulation, and TLR4 and NF-κB
expression was inhibited after AST-IV treatment
(Fig. 3A, B). Similar results were observed by Western blot, which showed significantly inhibited TLR4
and NF-κB expression by AST-IV treatment at both
concentrations of 1 and 5 μmol/l, while MyD88
expression was inhibited when 5 μmol/l of AST-IV
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was added (Fig. 3C; p < 0.05). Thus, AST-IV exerts
a suppressive effect on TLR4-MyD88 signalling
pathway.

Effect of AST-IV on LPS-induced
microglia polarization
We then studied whether AST-IV can trigger the
polarization of BV-2 microglia, and shift from
inflammatory M1 cells toward anti-inflammatory M2 cells. As shown in Figure 4, LPS stimulated
the upregulation of IL-1β and iNOS (p < 0.01,
p < 0.000), and the treatment of AST-IV effectively inhibited the expression of IL-1β and iNOS
(Fig. 4; p < 0.05, p < 0.05, p < 0.000). In contrast,
AST-IV treatment upregulated Arg-1 expression
(Fig. 4, p < 0.05, p < 0.01). The results clearly indicated that AST-IV treatment converted LPS-induced
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inflammatory M1 phenotype toward an anti-inflammatory M2 phenotype.

Effect of AST-IV on cytokine production
of microglia
To further address the effect of AST-IV on the
microglia phenotype, cytokines IL-6, TNF-α, IL-4
and IL-10 in BV-2 microglia culture supernatants
were measured by ELISA. LPS stimulated BV-2 cells
to produce higher amounts of IL-6 (p < 0.01), TNF-α
(p < 0.05) but reduced IL-10 (p < 0.01) compared
to non-stimulated cells (Fig. 5). The production of
IL-6 and TNF-α was significantly inhibited when
treated by AST-IV (all p < 0.01). In addition, treated
by AST-IV increases IL-10 production compared to
that treated with LPS (Fig. 5, p < 0.05). Meanwhile,
AST-IV treatment had a tendency to increase IL-4
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Fig. 4. AST-IV effectively inhibited the expression of IL-1β and iNOS and upregulated Arg-1 expression. The
BV-2 cells were cultured in 6-well plates with LPS (1 μg/ml)/AST-IV (1 μmol/l and 5 μmol/l) for 24 h. The
protein was extracted from BV-2 cells, and the expression of IL-1β, iNOS and Arg-1 were measured using
Western blotting. ∆p < 0.05, ∆∆p < 0.01 vs. LPS(–) AST-IV(–), ∆∆∆p < 0.000 vs. LPS(+) AST-IV(–), *p < 0.05,
**p < 0.01, ***p < 0.000 vs. LPS(+) AST-IV(–).

production, while it did not reach statistical significance (Fig. 5).

BV-2-conditioned medium treated
with AST-IV exhibits a neuroprotective
effect
Finally, we collected BV-2 microglia-conditioned
medium treated with AST-IV (1 and 5 μmol/l) and
determined its neuroprotective effect when exposing cultured PC12 neurons, using MTT assay. The
results showed that, while supernatants of LPS-stimulated microglia induced neuron death, AST-IV-conditioned medium significantly increased cell viability
compared to LPS-stimulated BV-2 microglia medium
(Fig. 6, p < 0.05, p < 0.01).
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Discussion
Microglia are unique resident immune cells and
major cellular source of inflammatory mediators in
the CNS, and a key player in the inflammatory processes related to neurodegenerative diseases [11].
Microglial activation is a double-edged sword in the
CNS which are related to both the immune response
and maintaining homeostasis [6,14]. Many studies
have demonstrated that microglia/macrophages
undergo M1 or M2 polarization in response to different environmental stimulation. M1 microglia/
macrophages can secrete a large number of inflammatory mediators and upregulate IL-1β and iNOS
expression. These changes can create an inflammatory microenvironment and then promote the
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Fig. 5. AST-IV decreased the production of IL-6 and TNF-α and increased IL-10 production in BV-2 microglia compared to those treated with LPS. BV-2 cells were treated with LPS (1 μg/ml)/AST-IV (1 μmol/l and
5 μmol/l) for 24 h. The levels of IL-6, TNF-α, IL-1β, IL-4 and IL-10 in culture supernatants were measured by
ELISA assay. Quantitative results are expressed as mean ± SEM from three independent experiments with
similar results. ∆p < 0.05, ∆∆p < 0.01 vs. LPS(–) AST-IV(–), **p < 0.01 vs. LPS(+) AST-IV(–).

pathogenesis of neurodegenerative diseases [15].
On the other hand, M2-polarized microglia/macrophages upregulate Arg-1 expression and increase
anti-inflammatory IL-10 and IL-4 production, which
can inhibit an inflammatory response and promote
neuroprotection [2,28,33]. Inhibiting microglial activation and the release of pro-inflammatory media-
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tors and promoting microglia polarization towards
M2 phenotype may, therefore, be crucial for the
treatment and neurodegenerative diseases.
The morphology and function of microglia adapt
to their ever-changing surroundings. Microglia in
the resting state, participants in CNS homeostasis, continuously scan the surrounding extracellu-
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150
Cell viability (% of control)

lar space and communicate directly with neurons,
astrocytes, and blood vessels [19]. When tumours,
brain damage, infection, stroke attract, microglia
transform into activated morphology, the phenotype, for responding to neuroinflammation. Activated microglia triggers a complex molecular cascade
including nitric oxide, oxygen free radicals, proteases and inflammatory cytokines production, a complex inflammatory response, and the blood-brain
barrier disruption, finally necrotic and apoptotic cell
death [27]. Resting BV-2 microglia are characterized
by round bodies, smooth-surface clear in cell edge
and cytoplasmic bright, whereas activated BV-2
cellular morphology like a broken egg or amoeboid
cell shape, swollen cell body, blur in the edge, and
dim cytoplasm [3]. The present study observed that
AST-IV treated LPS-induced BV-2 cells retained
the shape that is characteristic of non-stimulated
microglia, indicating an inhibitory effect of this small
molecule on microglia activation.
The activated microglia release inflammatory
cytokines including IL-6, TNF-α, and other cytotoxic
molecules such as NO [22]. Here, we found that IL-6,
IL-1β and TNF-α levels increased in the LPS-treated only group, while AST-IV treatment could inhibit these abnormal increases and enhance IL-10
secretion. These results demonstrate that AST-IV
treatment exerts neuroprotective effects possibly
through its anti-inflammatory properties. Furthermore, we selected the markers of M1 polarization,
i.e. iNOS and IL-1β, as well as the markers of M2
polarization, i.e. Arg-1. While M1 markers were significantly declined, M2 markers were significantly
increased in AST-IV treatment compared with LPS
treatment. Thus, AST-IV can shift microglia from M1
to M2 phenotype.
AST-IV has been reported to exert anti-inflammatory and neuroprotective effects in various disease
models [21,31]. AST-IV-induced anti-inflammatory effects indicate its potential application in the
treatment of neuroinflammatory and neurodegenerative diseases [12,34]. AST-IV can attenuate the
H2O2-induced apoptosis of neuronal cells and exert
protective effects against neurodegenerative diseases via the p38 MAPK pathway, and attenuate glutamate-induced neurotoxicity in PC12 cells through
Raf-MEK-ERK pathway [24,37]. In the present study
we showed that AST-IV reduces microglial activation
and attenuate microglia-mediated neuronal damage.
These results provide evidence that the mechanism

100
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Fig. 6. AST-IV-conditioned medium increases the
survival of cultured PC12 neurons. BV-2 cells were
cultured with LPS (1 μg/ml)/AST-IV (1 μmol/l and
5 μmol/l) for 24 h, and conditioned media were
collected. PC12 neurons were then incubated
for 24 h with the different conditioned media.
PC12 neurons viability were quantified with
MTT. Quantitative results are expressed as mean
± SEM from five independent experiments with
similar results. ∆∆p < 0.01 vs. LPS(–) AST-IV(–),
*p < 0.05, **p < 0.01 vs. LPS(+) AST-IV(–).

underlying the neuroprotective effects of AST-IV
may occur through inhibiting microglial activation
and shifts microglia from the M1 to M2 phenotype.
The diversity of the macrophage function is related to many factors, including cytokines, chemokines,
local micro environmental conditions, protein kinases, hormones, TLR ligands, complement and other
endogenous molecules [1,17,32]. Among them, TLRs
play an important role in the innate immune system [8]. Although TLR4 expressed on multiple cell
lines, such as microglia, astrocytes and neurons,
its expression is highest on microglia [20]. LPS is
recognized by TLR4 on the surface of microglia
and induces TLR4 activation, which subsequently recruits the adapter protein MyD88 and leads
to the rapid activation of NF-κB. Overactivation of
the NF-κB signalling pathway causes the excessive
production of pro-inflammatory cytokines and triggers an array of microglia responses leading to the
release of inflammatory mediators [16,30]. A recent
study has shown that LPS can shift microglia from
M0 to M1 phenotype by stimulating the activation
of TLR4/p-38/p-JNK/NF-κB signalling pathway [36].
LPS binds to TLR4 on the surface of microglia cells,
resulting in the overexpression of proinflammato-
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ry genes and over-secretion of pro-inflammatory
molecules by NF-κB activation [25]. The activation
and nuclear translocation of NF-κB is a key step in
LPS-stimulated microglial activation, and regulates
the expression of a large number of inflammatory
genes [9]. It has been reported that AST-IV exerted
its anti-inflammatory effect via inhibition of glucocorticoid receptor-mediated NF-κB signalling [23],
and attenuated release of inflammatory cytokines is
related to inhibiting the TLR4/NF-kB signalling pathway [35]. In this study, AST-IV suppressed the protein
expression of TLR4, MyD88 and NF-κB of microglia,
which probably resulted in the decreased production
of pro-inflammatory molecules, and shifted these
cells to the M2 phenotype.
In conclusion, the present study demonstrates
that AST-IV exerts anti-inflammatory effects and
attenuates microglia-mediated neuronal damage.
These effects are possible through inhibiting TLR4/
MyD88/NF-κB signalling pathways, thus reducing
the expression of pro-inflammatory mediators including TNF-α, IL-1β, IL-6, iNOS, and inducing the
expression of anti-inflammatory molecules, e.g.,
IL-10 and Arg-1, and regulating microglia polarization from inflammatory M1 to an anti-inflammatory
M2 state. Our observations suggest that AST-IV has
the potential to be used as a therapeutic agent for
neurodegenerative diseases.
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